155 related articles for article (PubMed ID: 32223235)
1. Discovery of Selective Small Molecule Degraders of BRAF-V600E.
Han XR; Chen L; Wei Y; Yu W; Chen Y; Zhang C; Jiao B; Shi T; Sun L; Zhang C; Xu Y; Lee MR; Luo Y; Plewe MB; Wang J
J Med Chem; 2020 Apr; 63(8):4069-4080. PubMed ID: 32223235
[TBL] [Abstract][Full Text] [Related]
2. BRAF
Feng L; Li J; Bu X; Zuo Y; Shen L; Qu X
Biochem Biophys Res Commun; 2020 Mar; 524(1):28-35. PubMed ID: 31980175
[TBL] [Abstract][Full Text] [Related]
3. Development of a potent small-molecule degrader against oncogenic BRAF
Ohoka N; Suzuki M; Uchida T; Tsukumo Y; Yoshida M; Inoue T; Ohki H; Naito M
Cancer Sci; 2022 Aug; 113(8):2828-2838. PubMed ID: 35579105
[TBL] [Abstract][Full Text] [Related]
4. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
5. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
6. Structure-Based De Novo Design for the Discovery of Miniprotein Inhibitors Targeting Oncogenic Mutant BRAF.
Ham JM; Kim M; Kim T; Ryu SE; Park H
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791574
[TBL] [Abstract][Full Text] [Related]
7. Resistance mechanism of the oncogenic β3-αC deletion mutation in BRAF kinase to dabrafenib and vemurafenib revealed by molecular dynamics simulations and binding free energy calculations.
Niu Y; Zhang Y; Yao X
Chem Biol Drug Des; 2019 Feb; 93(2):177-187. PubMed ID: 30225883
[TBL] [Abstract][Full Text] [Related]
8. Degradation of AMPK-α1 sensitizes BRAF inhibitor-resistant melanoma cells to arginine deprivation.
Li YY; Wu C; Shah SS; Chen SM; Wangpaichitr M; Kuo MT; Feun LG; Han X; Suarez M; Prince J; Savaraj N
Mol Oncol; 2017 Dec; 11(12):1806-1825. PubMed ID: 29094484
[TBL] [Abstract][Full Text] [Related]
9. BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma.
Walter L; Heinzerling L
Anticancer Res; 2018 Mar; 38(3):1335-1341. PubMed ID: 29491057
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the research and development of B-Raf inhibitors.
Li HF; Chen Y; Rao SS; Chen XM; Liu HC; Qin JH; Tang WF; Yue-Wang ; Zhou X; Lu T
Curr Med Chem; 2010; 17(16):1618-34. PubMed ID: 20345352
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
12. Biochemical Characterization of Full-Length Oncogenic BRAF
Cope N; Novak B; Candelora C; Wong K; Cavallo M; Gunderwala A; Liu Z; Li Y; Wang Z
Chembiochem; 2019 Nov; 20(22):2850-2861. PubMed ID: 31152574
[TBL] [Abstract][Full Text] [Related]
13. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
Dankner M; Rose AAN; Rajkumar S; Siegel PM; Watson IR
Oncogene; 2018 Jun; 37(24):3183-3199. PubMed ID: 29540830
[TBL] [Abstract][Full Text] [Related]
14. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
[TBL] [Abstract][Full Text] [Related]
15. PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma.
Deuker MM; Marsh Durban V; Phillips WA; McMahon M
Cancer Discov; 2015 Feb; 5(2):143-53. PubMed ID: 25472943
[TBL] [Abstract][Full Text] [Related]
16. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
17.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
18. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
Wang H; Quan H; Lou L
Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties.
Ott PA; Henry T; Baranda SJ; Frleta D; Manches O; Bogunovic D; Bhardwaj N
Cancer Immunol Immunother; 2013 Apr; 62(4):811-22. PubMed ID: 23306863
[TBL] [Abstract][Full Text] [Related]
20. Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma.
Rose AAN
Drugs Today (Barc); 2019 Apr; 55(4):247-264. PubMed ID: 31050693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
